Changes in Alcohol Consumption following Direct-Acting Antiviral Treatment for Hepatitis C in VA Patients with Comorbid Alcohol Use Disorder and PTSD

Hoyt, Jessica E.; Teja, Nikhil; Jiang, Tammy; Rozema, Luke; Gui, Jiang; Watts, Bradley V.; Shiner, Brian; Gradus, Jaimie L.

doi:10.1080/15504263.2022.2123119

Cited by 3 publications

(2 citation statements)

References 70 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Scarce evidence associates DAA treatment with declined frequency of alcohol misuse and mean improvement in AUDIT-C scores. 138,139 Semistructured interviews elucidate that after SVR some patients felt released from earlier limitations, but the majority maintain high concern about liver status and attentive to their health. 140 So, it would be important future research on lifestyle characterization and its impact on cardiovascular damage and reduce risk of disease progression.…”

Section: Discussionmentioning

confidence: 99%

“…Noteworthy, these results do not consider lifestyle changes (i.e., alcohol drinking habits) that may follow DAA treatment/SVR achievement and could impact metabolic parameters. Scarce evidence associates DAA treatment with declined frequency of alcohol misuse and mean improvement in AUDIT‐C scores 138,139 . Semistructured interviews elucidate that after SVR some patients felt released from earlier limitations, but the majority maintain high concern about liver status and attentive to their health 140 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, and associated metabolic comorbidities: A systematic review

Cespiati,

Coelho Rodrigues,

Santos

et al. 2024

Liver International

View full text Add to dashboard Cite

Background and AimsThe beneficial effect of Hepatitis C virus (HCV) eradication by direct antiviral agents (DAAs) on liver fibrosis is well defined. Despite this, the impact of viral eradication in both hepatic and extra‐hepatic metabolic features is underreached. This systematic review aimed to synthesize the evidence on the impact of HCV eradication by DAAs on liver steatosis, carotid atherosclerosis, glucidic impairment, dyslipidaemia, and weight gain.MethodsA systematic search of the existing literature (up to December 2022) identified 97 original studies that fulfilled the inclusion criteria.ResultsWhereas total cholesterol and low‐density lipoprotein (LDL) seem to increase after viral eradication, the cardiovascular damage expressed as carotid plaques and intima‐media thickness seems to improve. Otherwise, the effect on liver steatosis, glucidic homeostasis, and weight seems to be strictly dependent on the presence of baseline metabolic disorders.ConclusionDespite high heterogeneity and relatively short follow‐up of included studies, we can conclude that the presence of metabolic risk factors should be strictly evaluated due to their impact on liver steatosis, glucidic and lipid homeostasis, and on weight gain to better identify patients at risk of liver disease progression despite the virus eradication.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%